NASDAQ:MSLE Satellos Bioscience Q2 2026 Earnings Report $9.05 +0.39 (+4.52%) As of 09:31 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Satellos Bioscience EPS ResultsActual EPS-$0.56Consensus EPS -$0.38Beat/MissMissed by -$0.18One Year Ago EPSN/ASatellos Bioscience Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASatellos Bioscience Announcement DetailsQuarterQ2 2026Date8/13/2026TimeAfter Market ClosesConference Call DateThursday, August 13, 2026Conference Call Time4:00PM ETConference Call ResourcesPress ReleaseEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release Satellos Bioscience Earnings HeadlinesQ3 EPS Estimate for Satellos Bioscience Reduced by AnalystAugust 21, 2026 | americanbankingnews.comSatellos Bioscience IncJuly 30, 2026 | cnn.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.August 31 at 1:00 AM | Profits Run (Ad)Satellos’ oral DMD drug improves arm movement after six months in Phase IIJuly 10, 2026 | msn.comSatellos Bioscience Duchenne drug candidate's interim data boosts confidenceJuly 8, 2026 | msn.comSatellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults ...July 8, 2026 | tmcnet.comSee More Satellos Bioscience Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Satellos Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Satellos Bioscience and other key companies, straight to your email. Email Address About Satellos BioscienceSatellos Bioscience (NASDAQ:MSLE) is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company's lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc., formerly known as iCo Therapeutics Inc., is based in Toronto, Ontario.View Satellos Bioscience ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 08/24 - 08/28From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens3 Retail Stocks to Watch After a Big Consumer Earnings WeekRubrik’s AI Security Bet Could Power the Next Leg HigherPalo Alto’s Rally Has One Big Problem Ahead of EarningsDLocal Is Testing the Breakout Level That Could Change Its Stock StoryIREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings Upcoming Earnings Medtronic (9/1/2026)Dell Technologies (9/1/2026)Palo Alto Networks (9/1/2026)Broadcom (9/2/2026)Hewlett Packard Enterprise (9/2/2026)Snowflake (9/2/2026)Ciena (9/3/2026)Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
